⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399333 | 0.83 | — | — | |
| SCHEMBL387047 | 0.81 | OPRM1 (0.39) | — | |
| SCHEMBL3174994 | 0.81 | — | — | |
| SCHEMBL4448677 | 0.78 | DNM1 (0.36) | — | |
| SCHEMBL8171362 | 0.74 | — | — | |
| SCHEMBL12475355 | 0.73 | — | — | |
| SCHEMBL1705389 | 0.71 | — | — | |
| SCHEMBL464424 | 0.71 | — | — | |
| SCHEMBL6157665 | 0.71 | — | — | |
| SCHEMBL4606903 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021038637-A1 | NOVEL VITAMIN A DERIVATIVE AND METHOD FOR PRODUCING SAME | リファインホールディングス株式会社 | 2021-03-04 | — | — | WO | disclosed |
| EP-2722051-B1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | SEATTLE GENETICS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-2845866-B1 | Antibodies and immunoconjugates and uses therefor | GENENTECH INC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-1917020-B1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS INC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2447282-B1 | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof | GENENTECH INC (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2353611-B1 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2446904-B1 | Anti-CD22 antibodies, their immunoconjugates and uses thereof | GENENTECH INC (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2845866-A1 | Antibodies and immunoconjugates and uses therefor | Genentech, Inc. (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2502938-B1 | Antibodies and immunoconjugates and uses therefor | GENENTECH INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2502938-A2 | Antibodies and immunoconjugates and uses therefor | Genentech, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1545613-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | Seattle Genetics, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004010957-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-5621133-A | PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES | DENINNO MICHAEL P (US) | 1997-04-15 | — | — | US | disclosed |
| US-5591884-A | PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996038435-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4994486-A | Neurological disorders | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |